68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Study Details
Study Description
Brief Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Early Phase 1 |
Detailed Description
Conventional 18F-FDG PET/CT has important diagnostic value in cell metabolism level, early metastasis, judging malignant potential and prognosis of tumors. It has been routinely used for staging and restaging of most tumors, but there are still some tumors with low uptake of 18F-FDG PET/CT. Receptor imaging with a single target also has some limitations in clinical application. For example, not all diseased cells express a large amount of single receptor on the surface, which greatly affects the judgment of the nature of the lesion. The dual-target molecular imaging based on GRPr expressed in the lesion site and integrin αvβ3 receptor highly expressed on the surface of the lesion neovascularization will overcome the above limitations and make full use of the advantages of the dual-target molecular imaging, which will greatly assist the diagnosis of malignant tumors such as breast\brain\prostate tumor which have high GRPr and αvβ3 receptor expression . In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for PET/CT imaging of breast\brain\prostate cancer, compared with conventional 18F-FDG, or single target imaging agent 68Ga-RGD or 68Ga-RM26 PET/CT imaging.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 68Ga-RM26-RGD and 18F-FDG PET/ CT scan Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 18F-FDG, respectively. |
Drug: 68Ga-RM26-RGD
Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Other Names:
Drug: 18F-FDG
18F-FDG injection
Other Names:
|
Experimental: 68Ga-RM26-RGD and 68Ga-RM26 PET/ CT scan Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively. |
Drug: 68Ga-RM26-RGD
Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Other Names:
Drug: 68Ga-RM26
Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Other Names:
|
Experimental: 68Ga-RM26-RGD and 68Ga-RGD PET/ CT scan Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RGD, respectively. |
Drug: 68Ga-RM26-RGD
Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Other Names:
Drug: 68Ga-RGD
Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Diagnostic performance1 [through study completion, an average of 1 year]
comparing the SUV and number of primary or metastasis lesions detected by 68Ga-RM26-RGD and 18F-FDG PET/CT
- Diagnostic performance2 [through study completion, an average of 1 year]
comparing the SUV and number of primary or metastasis lesions detected by 68Ga-RM26-RGD and 68Ga-RM26 PET/CT
- Diagnostic performance3 [through study completion, an average of 1 year]
comparing the SUV and number of primary or metastasis lesions detected by 68Ga-RM26-RGD and 68Ga-RGD PET/CT
Secondary Outcome Measures
- The dosimetry of 68Ga-RM26-RGD [through study completion, an average of 1 year]
Measure the distribution of 68Ga-RM26-RGD in GRPR and αvβ3 positive tumor patients by 2-hour dynamic PET/CT acquisition by dosimetry software
- 68Ga-RM26-RGD uptake at different tumors [through study completion, an average of 1 year]
The SUV uptake of tumors and metastases in patients with breast/brain/prostate cancer was measured.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patients with confirmed or suspected breast/brain/prostate cancer;
-
68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
-
signed written consent.
Exclusion Criteria:
-
pregnancy;
-
breastfeeding;
-
any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Peking Union Medical College Hospital | Beijing | China |
Sponsors and Collaborators
- Peking Union Medical College Hospital
Investigators
- Principal Investigator: Zhaohui Zhu, MD,PHD, Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PUMCH-NM-RR